Biodesix, Inc.

Industry

  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Chemistry, Immunoassay
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Digital Health
    • Disease Management
    • Artificial Intelligence

Other Names/Subsidiaries

  • Homestead Clinical
  • Indi
  • Integrated Diagnostics
See more in Biomedtracker

Latest on Biodesix, Inc.

Scrip

Gilead Waives Acquisition Option As Pionyr Explores Other Strategies

 
• By Ayisha Sharma

Following a mutual agreement, Gilead Sciences, Inc. has waived its option to acquire Pionyr Immunotherapeutics Inc. for a pre-set price, enabling Pionyr to shop around for new opportunities as mac

Medtech Insight

Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions

 
• By Deanna Kamienski and Maureen Riordan

Medical Device Acquisitions The first quarter featured 24 device M&A transactions, 17 of which had disclosed values that together totaled $10.2bn, versus the fourth quarter of 2020, when 21 deals tota

Scrip

Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies

 
• By Scrip Team

Neurimmune, Ethris Partner On Inhaled Antibody To Treat COVID-19 Neurimmune AG in Zurich, Switzerland and Ethris GmbH in Munich, Germany announced on 1 April that they have agreed to collaborate o

Scrip

Tivozanib Non-Oncology Buy-Back Gives Quick Cash To AVEO

 
• By Ian Haydock

Japan's Kyowa Hakko Kirin Co. Ltd. (KHK) has reacquired global rights to tivozanib in non-oncology settings from licensee Aveo Pharmaceuticals Inc. , which will now focus its efforts on development